Maximus Reports Fiscal 2025 Revenue of $5.43 Billion and Adjusted EPS of $7.36

Reuters
Nov 20
Maximus Reports Fiscal 2025 Revenue of $5.43 Billion and Adjusted EPS of $7.36

Maximus Inc. reported full year revenue of $5.4 billion for fiscal year 2025, a 2.4% increase from the prior year, with organic growth of 3.9% mainly driven by higher demand for clinical services in the U.S. Federal Services Segment. The company achieved an operating margin of 9.7% and an adjusted EBITDA margin of 12.9%. Diluted earnings per share were $5.51, and adjusted diluted earnings per share were $7.36. Cash flows from operating activities totaled $429 million, and free cash flow was $366 million. Maximus repurchased 5.8 million shares for $457 million during the year. The leverage ratio at the end of the period was 1.5x. For fiscal year 2026, the company expects free cash flow between $450 million and $500 million and plans to focus on expansion in U.S. Federal markets and AI-enabled automation. A quarterly cash dividend of $0.30 per share is payable on December 1, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maximus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120109408) on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10